The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

artaxbiopharma.com

Founded Year

2013

Stage

Series C | Alive

Total Raised

$44.18M

Last Raised

$26M | 5 mos ago

About Artax Biopharma

Artax Biopharma is a clinical-stage biopharmaceutical company that develops therapies for autoimmune diseases. Its pipeline of drugs is based on science that targets the interaction between T-cell receptors (TCR) and Nck, a key protein involved in T-cell activation. The company was founded in 2013 and is based in Cambridge, Massachusetts.

Artax Biopharma Headquarter Location

1 Broadway 14th Floor

Cambridge, Massachusetts, 02142,

United States

617-401-2168

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Artax Biopharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Artax Biopharma is included in 2 Expert Collections, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Artax Biopharma Patents

Artax Biopharma has filed 6 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/20/2020

5/18/2021

Clusters of differentiation, Immune system, Immunology, Autoimmune diseases, Transcription factors

Grant

Application Date

5/20/2020

Grant Date

5/18/2021

Title

Related Topics

Clusters of differentiation, Immune system, Immunology, Autoimmune diseases, Transcription factors

Status

Grant

Latest Artax Biopharma News

Artax Biopharma Closes $26M Financing Round

May 12, 2022

FinSMEs Search for: Artax Biopharma , a Cambridge, MA-based clinical stage biotechnology company, raised $26M in funding. The round was led by Eli Lilly and Company and Sound Bioventures with participation from Advent Life Sciences, Columbus Venture Partners, and Belinda Termeer and other shareholders. The company intends to use the funds to develop AX-158, its first oral small molecule immunomodulating agent. Led by Joseph Lobacki, Chief Executive Officer, Artax Biopharma is a clinical-stage biotechnology company transforming T Cell-mediated disease treatment by developing innovative small molecules that modulate the immune system. Artax science holds broad potential to treat T Cell-mediated diseases such as autoimmune diseases; induced T cell pathologies (such as acute graft-versus-host disease and immune-oncology treatment-related adverse events); and T Cell malignancies, while simultaneously allowing the body to fight foreign pathogens. AX-158 is a first-in-class, oral small molecule immunomodulating agent in clinical development for the treatment of T Cell-mediated diseases. It employs a first-in-class mechanism of action that selectively modulates inappropriate T cell activation, a cause of autoimmune disease. AX-158 has the potential to treat T Cell-mediated diseases without the risk of immunosuppression. Artax’s ongoing Phase 1 clinical trial is assessing the safety, exposure, and pharmacokinetics of AX-158 in healthy volunteers and includes ex vivo stimulated measures of its pharmacodynamic activity. In preclinical studies, AX-158 demonstrated potential to treat T Cell-mediated diseases by decreasing key cytokines including INFγ, TNFα, IL-2, IL-1 and IL-6 in whole human blood samples. FinSMEs 12/05/2022

  • When was Artax Biopharma founded?

    Artax Biopharma was founded in 2013.

  • Where is Artax Biopharma's headquarters?

    Artax Biopharma's headquarters is located at 1 Broadway, Cambridge.

  • What is Artax Biopharma's latest funding round?

    Artax Biopharma's latest funding round is Series C.

  • How much did Artax Biopharma raise?

    Artax Biopharma raised a total of $44.18M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.